

ALLERGAN INC  
Form 4  
March 19, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Diradoorian Raymond H

(Last) (First) (Middle)  
2525 DUPONT DRIVE  
(Street)

IRVINE, CA 92612

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
ALLERGAN INC [AGN]

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/17/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
EVPGlobal Technical Operations

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2015		G	V	1,075	D	\$ 0 5,498
Common Stock	03/17/2015		A		7,891.868 (1)	A	\$ 0 13,389.868
Common Stock	03/17/2015		D		13,389.868 (2)	D	(2) 0
Common Stock	03/17/2015		D		6,751.7228 (2)	D	(2) 0 I By 401(k)
Common Stock	03/17/2015		D		4,774.2478 (2)	D	(2) 0 I By Esop

Edgar Filing: ALLERGAN INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 58.55	03/17/2015		D	23,000 (3)	(4) 02/02/2017	Common Stock 23,000
Employee Stock Option (Right to Buy)	\$ 64.47	03/17/2015		D	60,000	(4) 02/14/2018	Common Stock 60,000
Employee Stock Option (Right to Buy)	\$ 40.16	03/17/2015		D	71,900	(4) 02/20/2019	Common Stock 71,900
Employee Stock Option (Right to Buy)	\$ 59.13	03/17/2015		D	55,000	(4) 02/22/2020	Common Stock 55,000
Employee Stock Option (Right to Buy)	\$ 75.58	03/17/2015		D	78,000	(4) 02/17/2021	Common Stock 78,000
Employee Stock Option	\$ 87.91	03/17/2015		D	38,000	(4) 02/17/2022	Common Stock 38,000

(Right to Buy)

Employee Stock

Option	\$ 105.87	03/17/2015	D	40,000	<u>(4)</u>	02/21/2023	Common Stock	40,000
--------	-----------	------------	---	--------	------------	------------	--------------	--------

(Right to Buy)

Employee Stock

Option	\$ 125.07	03/17/2015	D	44,111	<u>(4)</u>	02/21/2024	Common Stock	44,111
--------	-----------	------------	---	--------	------------	------------	--------------	--------

(Right to Buy)

## Reporting Owners

Reporting Owner Name / Address	Relationships			Other
	Director	10% Owner	Officer	
Diradoorian Raymond H 2525 DUPONT DRIVE IRVINE, CA 92612			EVP Global Technical Operations	

## Signatures

/s/ Matthew J. Maletta, attorney-in-fact for Raymond H.

Diradoorian

03/18/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents 7,890 performance-based restricted stock units granted on October 29, 2014 and 1.868 dividend equivalent rights acquired with respect to each vested restricted stock unit (collectively, the "RSUs"). The RSUs vested in full on the Effective Date pursuant to the terms of the Merger Agreement (each as defined below).

(2) Pursuant to that certain Agreement and Plan of Merger dated November 16, 2014, (the "Merger Agreement") by and among the Issuer, Actavis, Plc ("Actavis") and a wholly-owned subsidiary of Actavis, the Issuer became an indirect wholly-owned subsidiary of Actavis upon consummation of the merger (the "Effective Date"). Each share of common stock was disposed of in exchange for \$129.22 cash plus 0.3683 of an Actavis ordinary share, having a market value of \$307.51 per share on the Effective Date.

(3) The option was previously reported as covering 23,000 shares at an exercise price of \$117.10. The issuer effected a two-for-one stock split on June 22, 2007, which resulted in 46,000 shares held by the reporting person at an exercise price of \$58.55. Twenty-three thousand (23,000) shares subject to the option were exercised prior to the Effective Date.

(4) Each option vested in full on the Effective Date and was cancelled in exchange for a cash payment equal to the number of shares subject to the option immediately prior to the merger, multiplied by the difference between (i) 0.3683 times \$294.1509 (which represents the 10-day volume weighted average price of Actavis stock starting on the 11th trading day prior to the closing) plus \$129.22 and (ii) the exercise price of the option, subject to the applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.